Mounjaro Formulation
No, Mounjaro (tirzepatide) does not come as an oral medication—it is only available as a once-weekly subcutaneous injection. 1
Current Formulation
Tirzepatide is formulated exclusively as a once-weekly subcutaneous (SC) injection with a half-life of approximately 5 days (116.7 hours) 1, 2. The medication is administered via:
- Single-dose prefilled pens
- Single-dose vials 3
The injection can be given in the abdomen, thigh, or upper arm, with similar bioavailability across all sites 2.
Dosing Schedule
Tirzepatide requires monthly dose titration starting from 2.5 mg weekly up to a maximum of 15 mg weekly 1. The FDA-approved doses are 5 mg, 10 mg, and 15 mg per week for both type 2 diabetes (approved 2022) and obesity (approved 2023) 1.
Why No Oral Formulation Exists
Unlike semaglutide, which has both subcutaneous and oral formulations, tirzepatide is a dual GIP/GLP-1 receptor agonist with different molecular characteristics 1. The evidence shows:
- Oral semaglutide at 50 mg daily achieved 17.1% weight reduction in the OASIS-1 trial 1
- Tirzepatide has no approved oral formulation and all clinical trials (SURPASS, SURMOUNT) used subcutaneous administration 1, 3, 4
Clinical Implications
The subcutaneous-only route means:
- Patients must be comfortable with weekly self-injection
- No option for those who cannot tolerate injections
- Different from oral diabetes medications like metformin or oral semaglutide
- Requires proper injection technique training
If a patient specifically needs an oral incretin-based therapy, oral semaglutide (14 mg for diabetes, 50 mg for obesity) is the only FDA-approved oral GLP-1 receptor agonist option 1.